Oligomonocytic chronic myelomonocytic leukemia (chronic myelomonocytic leukemia without absolute monocytosis) displays a similar clinicopathologic and mutational profile to classical chronic myelomonocytic leukemia
暂无分享,去创建一个
Adam Bagg | Zhengming Chen | Wayne Tam | Eric Hsi | Sa A Wang | A. Bagg | W. Tam | D. Arber | C. Bueso-Ramos | Zhengming Chen | Sa A. Wang | E. Hsi | D. Hassane | Carlos Bueso-Ramos | R. Hasserjian | Robert P Hasserjian | Duane C Hassane | A. Orazi | J. Geyer | Julia T Geyer | Yen-Chun Liu | Jean Oak | Daniel A Arber | Heesun J Rogers | Katherine Levinson | Attilio Orazi | Yen‐Chun Liu | J. Oak | H. J. Rogers | K. Levinson
[1] I. Weissman,et al. Functionally distinct hematopoietic stem cells modulate hematopoietic lineage potential during aging by a mechanism of clonal expansion , 2010, Proceedings of the National Academy of Sciences.
[2] Zev N. Kronenberg,et al. Age-related mutations and chronic myelomonocytic leukemia , 2016, Leukemia.
[3] U. Germing,et al. The myelodysplastic/myeloproliferative neoplasms: myeloproliferative diseases with dysplastic features , 2008, Leukemia.
[4] Frequent Pathway Mutations of Splicing Machinery in Myelodysplasia , 2011 .
[5] M. Cazzola,et al. Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia. , 2016, Blood.
[6] Mingming Jia,et al. COSMIC: exploring the world's knowledge of somatic mutations in human cancer , 2014, Nucleic Acids Res..
[7] D. Birnbaum,et al. TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia , 2009, Haematologica.
[8] D. Birnbaum,et al. Gene mutations differently impact the prognosis of the myelodysplastic and myeloproliferative classes of chronic myelomonocytic leukemia , 2014, American journal of hematology.
[9] H. Gralnick,et al. Proposals for the Classification of the Acute Leukaemias French‐American‐British (FAB) Co‐operative Group , 1976, British journal of haematology.
[10] U. Germing,et al. Refined medullary blast and white blood cell count based classification of chronic myelomonocytic leukemias. , 2014, Leukemia research.
[11] T. Haferlach,et al. Recent advances in diagnosis, molecular pathology and therapy of chronic myelomonocytic leukaemia , 2011, British journal of haematology.
[12] L. Arenillas,et al. Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia. , 2013, Blood.
[13] Michael Heuser,et al. Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes. , 2012, Blood.
[14] Debashis Sahoo,et al. Human bone marrow hematopoietic stem cells are increased in frequency and myeloid-biased with age , 2011, Proceedings of the National Academy of Sciences.
[15] S. Corti,et al. RAS Mutations Contribute to Evolution of Chronic Myelomonocytic Leukemia to the Proliferative Variant , 2010, Clinical Cancer Research.
[16] Mario Cazzola,et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. , 2016, Blood.
[17] N. Harris,et al. The World Health Organization (WHO) classification of the myeloid neoplasms. , 2002, Blood.
[18] O. Hofmann,et al. VarDict: a novel and versatile variant caller for next-generation sequencing in cancer research , 2016, Nucleic acids research.
[19] R. Laborde,et al. Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes , 2013, Leukemia.
[20] B. Ko,et al. The clinical implication of SRSF2 mutation in patients with myelodysplastic syndrome and its stability during disease evolution. , 2012, Blood.
[21] H. Gralnick,et al. Proposals for the classification of the myelodysplastic syndromes , 1982, British journal of haematology.
[22] M. McCarthy,et al. Age-related clonal hematopoiesis associated with adverse outcomes. , 2014, The New England journal of medicine.
[23] Joshua F. McMichael,et al. Age-related cancer mutations associated with clonal hematopoietic expansion , 2014, Nature Medicine.
[24] Joaquín Dopazo,et al. SNPeffect 4.0: on-line prediction of molecular and structural effects of protein-coding variants , 2011, Nucleic Acids Res..
[25] F. Solé,et al. Targeted deep sequencing improves outcome stratification in chronic myelomonocytic leukemia with low risk cytogenetic features , 2016, Oncotarget.
[26] D. Birnbaum,et al. Prognostic score including gene mutations in chronic myelomonocytic leukemia. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] A. Orazi,et al. Myeloproliferative neoplasms (BCR‐ABL1 negative) and myelodysplastic/myeloproliferative neoplasms: current diagnostic principles and upcoming updates , 2016, International journal of laboratory hematology.
[28] S. Ogawa,et al. SRSF2 mutations in 275 cases with chronic myelomonocytic leukemia (CMML). , 2012, Blood.
[29] Martin Dugas,et al. Next-generation sequencing technology reveals a characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia by detecting frequent alterations in TET2, CBL, RAS, and RUNX1. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] G. Mufti,et al. An International MDS/MPN Working Group’s perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic/myeloproliferative neoplasms , 2015, Haematologica.